Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab plus ipilimumab versus platinum-pemetrexed chemotherapy for first-line unresectable pleural mesothelioma in China
CTR20212323Phase 2Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Mar 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab, ipilimumab in pleural mesothelioma, sponsored by Bristol Myers Squibb. Started Mar 2022; status: completed.
02
Drugs
nivolumabipilimumab
03
Conditions
pleural mesothelioma
Beyond the preview
Go deeper on CTR20212323.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20212323.